Back

Health-related quality of life and prognosis in cardiac sarcoidosis

30 August 2024 (08:00 - 17:30)
Organised by: Logo
Congress Presentation Part of: Left ventricular hypertrophy and hypertrophic cardiomyopathy: new findings Infiltrative Myocardial Disease ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Mrs Julia Raak-Tarkiainen

Helsinki University Central Hospital, Helsinki (Finland)

7 More presentations in this session

Presentation thumbnail
Mildly elevated left ventricular outflow tract gradients are associated with increased short term mortality in inpatients without septal hypertrophy
Doctor S. Khoury (Tel Aviv, IL)
Abstract Slides Video
Presentation thumbnail
Endomyocardial biopsy in the diagnosis of cardiac sarcoidosis
Ms H. Malkonen (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
Health-related quality of life disparity in cardiac sarcoidosis versus other myocardial diseases
Mrs J. Raak-Tarkiainen (Helsinki, FI)
Abstract Slides Video
Presentation thumbnail
Prevalence of transthyretin amyloid cardiomyopathy in patients with left ventricular hypertrophy: the RETTRACE Study
Doctor D. Tsilakis (Athens, GR)
Abstract Slides Video
Presentation thumbnail
The role of 18fluorine-fluorodeoxyglucose positron emission tomography in the diagnosis, follow-up, and regulation of treatment in patients with cardiac sarcoidosis.
Doctor E. Bobbio (Gothenburg, SE)
Abstract Slides Video

Access the full session

Session thumbnail
Left ventricular hypertrophy and hypertrophic cardiomyopathy: new findings

The Event

Event poster

ESC Congress 2024

30 August - 2 September 2024
You may be interested in
thumbnail
Congress Presentation
Health-related quality of life disparity in cardiac sarcoidosis versus other myocardial diseases
thumbnail
Congress Presentation
Association of left ventricular ejection fraction improvement with prognosis in patients with cardiac sarcoidosis: insights from the ILLUMINATE-CS study
thumbnail
Congress Presentation
The role of 18fluorine-fluorodeoxyglucose positron emission tomography in the diagnosis, follow-up, and regulation of treatment in patients with cardiac sarcoidosis.

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources